Please login to the form below

Not currently logged in
Email:
Password:

Teva's US approval for hypertension drugs

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure drugs Cozaar and Hyzaar

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure (hypertension) drugs Cozaar (losartan) and Hyzaar (hydrochlorothiazide and losartan), and intends to launch sales immediately.

Teva, the world's biggest generic drug producer, will have 180 days to market the generics exclusively, an award generally given to companies that challenge patents first.

An exclusivity period can allow generic companies a window of significant sales before rivals rush in and pricing freefalls.

Teva said a federal appeals court this week rejected an effort by generic drug producers Apotex and Roxane Laboratories to challenge Teva's right to that exclusivity period.

Last week, Apotex and Roxane sued the US Food and Drug Administration, arguing that a key patent for the drugs had expired and therefore no company was eligible for the exclusive rights.

Cozaar and Hyzaar, which have annual US sales of about $1.6bn, have been among Merck's biggest selling products, but the pharma company has been bracing for generic competition this year.

8th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics